In an important new development Swiss-based Debiopharm entered a Phase 3 trial of a new Octreotide formulation. The company is currently recruiting patients for the study. Debio 4126 is a sustained-release formulation designed to improve the convenience of somatostatin analogue (SSA) therapy for the treatment of acromegaly.
